Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907241 · ClinicalTrials.gov registry record · Phase 3
Clinical Phase III Study TO Monitor THE Safety, Tolerability AND Efficacy OF Subcutaneous Human Immunoglobulin (octanorm) IN Patients With Primary Immunodeficiency Diseases, Including (BUT NOT Limited TO) Those WHO Have Completed THE Scgam-01 Trial
A Phase 3 study, sponsored by Octapharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT03907241: Completed Phase 3 study, sponsored by Octapharma.
NCT03907241 is a Phase 3 study that has completed, run by Octapharma. The registered enrollment target is 27 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03907241, a Phase 3 study, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
Summary for SCGAM-03: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (Octanorm) in patients with primary immunodeficiency diseases who have completed the SCGAM-01 trial. Summary for SCGAM-03 in Canada: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (octanorm) in patients with primary immunodeficiency diseases, including (but not limited to) those who have completed the SCGAM-01 trial
Primary Outcome
Number of TEAEs
Interventions
- DRUG Octanorm 16.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2019-09-05 |
| Phase | Phase 3 |
What the finished NCT03907241 record still lists
NCT03907241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Octanorm 16.5% is the first listed.
NCT03907241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03907241 about?
NCT03907241 is a clinical study titled "Clinical Phase III Study TO Monitor THE Safety, Tolerability AND Efficacy OF Subcutaneous Human Immunoglobulin (octanorm) IN Patients With Primary Immunodeficiency Diseases, Including (BUT NOT Limited TO) Those WHO Have Completed THE Scgam-01 Trial". Summary for SCGAM-03: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (Octanorm) in patients with primary immunodeficiency diseases who have completed the SCGAM-01 trial. Summary for SCGAM-03 in Canada: Clinical phase III study to monit...
What is the current status of trial NCT03907241?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2016-03-01. Estimated completion is 2019-09-05.
What interventions are being tested in trial NCT03907241?
The interventions under investigation include: Octanorm 16.5% (DRUG).
Who is sponsoring clinical trial NCT03907241?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03907241's enrollment target sits among peer trials
27 1936th of 2000 higher than 64 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI